Transforming Human Pancreatic Cancer Into An Immunologic Disease

将人类胰腺癌转变为免疫疾病

• 批准号: 10408080
• 负责人: ELIZABETH M. JAFFEE
• 金额: $ 253.07万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10408080
• 关键词: Achievement; Address; Animal Model; Animals; Antigens; Bioinformatics; Biological Assay; Biological Markers; Biometry; Bypass; Cell physiology; Cells; Chemotherapy-Oncologic Procedure; Chronic; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials; Combined Modality Therapy; Complex; DNA analysis; Data; Databases; Dendritic cell tumor; Environment; Epigenetic Process; Feeds; Fibroblasts; Future; Generations; Genetic; Genomics; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitor; Human; Immune; Immune System Diseases; Immune checkpoint inhibitor; Immune response; Immunotherapy; Incidence; Infiltration; Inflammation; Inflammatory; Interleukin-8; KRAS2 gene; Malignant Neoplasms; Malignant neoplasm of pancreas; Mus; Mutate; Mutation; Myelogenous; Myeloid Cells; Myeloid-derived suppressor cells; Oncogene Activation; Outcome; Pancreas; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Patients; Population; Procedures; Proteomics; RNA analysis; Reaction; Regulation; Regulatory T-Lymphocyte; Reporting; Research Design; Research Personnel; Resistance; Science; Signal Transduction; Source; Standardization; Stromal Cells; Survival Rate; T cell response; T cell therapy; T-Lymphocyte; Technology; Testing; The Cancer Genome Atlas; Therapeutic; Therapeutic Intervention; Tumor Immunity; Tumor-associated macrophages; Tumor-infiltrating immune cells; Undifferentiated; Vaccines; angiogenesis; anti-CTLA4; anti-PD-1; arm; base; cell type; chemotherapy; combinatorial; data integration; design; digital pathology; effector T cell; genomic data; improved; innovation; monocyte; mouse model; multidisciplinary; neoantigen vaccine; neoantigens; novel; novel vaccines; pancreatic stellate cell; patient stratification; peripheral blood; pre-clinical; preclinical study; programs; recruit; standard of care; trafficking; translational clinical trial; treatment response; tumor; tumor microenvironment

Pancreatic ductal adenocarcinoma (PDA) is rising in incidence but remains deadly for most patients. Some progress has occurred in activating immune responses against PDA, however there are unanswered questions that need to be addressed for immunotherapy to have a significant impact on the lives of PDA patients. Our Team will address two critical problems: 1) inefficient generation of high quality T cells targeted against PDA antigens capable of tumor trafficking and killing; and 2) multiple cellular barriers that comprise stromal and myeloid cells that inhibit effector T cell trafficking and function in the PDA tumor microenvironment (TME). Both clinical studies (“science in patients”) and pre-clinical studies (mouse models) will be conducted to address these issues, and to evaluate novel combinatorial therapies that successfully modulate PDA stroma and chronic inflammation to facilitate improved tumor infiltration of high quality and durable cancer targeted T cells. This program is composed of 4 Projects and 4 Cores. The four projects will address the common overarching theme that PDA is composed of multiple cell types and signals that inhibit T cell induction, trafficking into, and function in tumors. Each project will address either the induction of quality T cells or the modulation of suppressive cell populations as major barriers to T cell infiltration and activation, and all will integrate agents that bypass these suppressive mechanisms with optimal T cell therapies. Projects 1, 2, and 4 will combine ongoing preclinical studies aimed at uncovering mechanisms of suppression of different barriers with translational clinical trials that study combination therapy to bypass these suppressive mechanisms. Project 3 will conduct a biomarker heavy clinical trial using a multi-arm Platform design that will add and delete immune modulatory arms based on data from biomarker analysis in this Project and from data that feeds into this Project from the other 3 Projects. Standard procedures will be used across Projects to collect and bank serial biospecimens obtained from patients treated on the clinical trials. The Cores will be critical for conducting the proposed assays and for analysis and integration of the data. A Program database will be developed to allow for integration of data generated from these assays across the entire Program. This will be a unique database that will also bring in data from other sources such as the TCGA database, and will provide the Program Team with the ability to compare results based on the genetics and inflammatory composition of each patient’s tumor and their response to the therapy they received. The final outcomes will include results from a number of therapeutic interventions, approaches to optimize each therapeutic, the potential to further integrate therapies that were tested in one or more projects in future trials, and the ability to develop TME signatures that may further stratify patients for therapeutic interventions. This program will substantially accelerate progress in PDA therapy, and allow otherwise nearly impossible achievements in defining predictors of successful immunological therapeutic intervention for PDAs.

胰腺导管腺癌（PDA）的发病率正在增加，但对于大多数患者而言仍然是致命的。一些 在激活针对PDA的免疫反应方面发生了进展，但是有未解决的问题 免疫疗法需要解决，以对PDA患者的生活产生重大影响。我们的 团队将解决两个关键问题：1）针对目标的高质量T细胞效率低下 PDA抗原能够贩运和杀死肿瘤； 2）多个完整基质的细胞屏障 和髓样细胞抑制PDA肿瘤微环境（TME）中的效应T细胞运输和功能。 将进行临床研究（“患者科学”）和临床前研究（小鼠模型）以解决 这些问题，并评估成功调节PDA基质和慢性的新型组合疗法 炎症以促进改善高质量和耐用癌症靶向T细胞的肿瘤浸润。这 程序由4个项目和4个核心组成。这四个项目将解决共同的总体主题 PDA由多种细胞类型和信号组成，这些细胞类型和信号抑制T细胞诱导，运输和功能 在肿瘤中。每个项目将解决质量T细胞的诱导或抑制性细胞的调节 种群是T细胞浸润和激活的主要障碍，所有人都将整合绕过这些的药物 具有最佳T细胞疗法的抑制性机制。项目1、2和4将结合正在进行的临床前 旨在通过翻译的临床试验来发现抑制不同障碍的机制， 研究组合疗法以绕过这些抑制性机制。项目3将进行生物标志物重型 使用多臂平台设计的临床试验，该设计将根据数据添加和删除免疫调节臂 从该项目中的生物标志物分析以及其他3个项目中为该项目提供的数据。 标准程序将在各个项目中使用，以收集和银行从患者那里获得的串行生物测量 在临床试验中进行治疗。核心对于进行拟议的测定和分析至关重要 数据集成。将开发一个程序数据库，以允许整合从 这些阿萨斯在整个程序中。这将是一个独特的数据库，也将引入其他数据库 诸如TCGA数据库之类的资源，并将为程序团队提供比较结果的能力 基于每个患者肿瘤的遗传学和炎症组成及其对治疗的反应 他们收到了。最终结果将包括许多治疗干预措施的结果， 优化每种疗法，进一步整合在一个或多个项目中测试的疗法的潜力 未来的试验以及开发TME特征的能力，可以进一步分类患者进行治疗 干预措施。该计划将大大加速PDA疗法的进展，并几乎允许 在定义PDA的成功免疫治疗干预预测指标方面的不可能成就。